Researchers assessed the management of hepatitis C Virus (HCV) infection, focusing on liver fibrosis and the impact of direct-acting antivirals (DAAs). Results showed that DAAs greatly enhance sustained virological response (SVR) rates in HCV, altering the disease progression and affecting extra-hepatic symptoms. mDAAs have high SVR rates and safety, effective even in severe fibrosis and cirrhosis, making fibrosis regression a key goal in HCV therapy. Researchers concluded that DAAs provide effective HCV treatment, but patients with advanced fibrosis or cirrhosis need continued monitoring for complications, such as hepatocellular carcinoma (HCC), and further study to fully understand long-term outcomes.

Reference: Carmona I, Cordero P, Ampuero J, et al. Role of assessing liver fibrosis in management of chronic hepatitis C virus infection. Clin Microbiol Infect. 2016 Oct;22(10):839-845. doi: 10.1016/j.cmi.2016.09.017. Epub 2016 Sep 24. PMID: 27677698.